ZHANG Lei,BI Qingqing,CHEN Wen, et al. Human Papillomavirus Genotype Prevalence and Attribution in Patients with Cervical Intraepithelial Neoplasia and Cancer [J]. Chinese General Practice, 2019, 22(17): 2042-2046. DOI: 10.12114/j.issn.1007-9572.2019.00.246.
张磊,毕庆庆,陈文等. 宫颈上皮内瘤变和宫颈癌患者人乳头瘤病毒基因型流行率和归因分析[J]. 中国全科医学, 2019, 22(17): 2042-2046. DOI: 10.12114/j.issn.1007-9572.2019.00.246.
[1]TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.DOI:10.3322/caac.21262.
[2]SCHIFFMAN M,CASTLE P E,JERONIMO J,et al.Human papillomavirus and cervical cancer[J].Lancet,2007,370(9590):890-907.DOI:10.1016/s0140-6736(07)61416-0.
[3]LI N,FRANCESCHI S,HOWELL-JONES R,et al.Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide:variation by geographical region,histological type and year of publication[J].Int J Cancer,2011,128(4):927-935.DOI:10.1002/ijc.25396.
[4]SASAGAWA T,MAEHAMA T,IDETA K,et al.Population-based study for human papillomavirus (HPV) infection in young women in Japan:a multicenter study by the Japanese Human Papillomavirus Disease Education Research Survey Group (J-HERS)[J].J Med Virol,2016,88(2):324-335.DOI:10.1002/jmv.24323.
[5]CHAN P K,CHEUNG T H,LI W H,et al.Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China[J].Int J Cancer,2012,131(3):692-705.DOI:10.1002/ijc.26404.
[6]谢通,江路,张泽菲,等.高危型HPV持续感染相关危险因素研究现状[J].现代妇产科进展,2017,26(11):860-862.DOI:10.13283/j.cnki.xdfckjz.2017.11.010.
XIE T,JIANG L,ZHANG Z F,et al.Current status of risk factors related to persistent high-risk HPV infection[J].Progress in Obstetrics and Gynecology,2017,26(11):860-862.DOI:10.13283/j.cnki.xdfckjz.2017.11.010.
[7]DE SANJOSE S,QUINT W G,ALEMANY L,et al.Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study[J].Lancet Oncol,2010,11(11):1048-1056.DOI:10.1016/S1470-2045(10)70230-8.
[8]FORMAN D,DE MARTEL C,LACEY C J,et al.Global burden of human papillomavirus and related diseases[J].Vaccine,2012,30(Suppl 5):F12-23.DOI:10.1016/j.vaccine.2012.07.055.
[9]LI Y,HUANG K,JI P L,et al.Cervical infection of oncogenic human papillomavirus (HPV) types in Beijing,China[J].Biomed Environ Sci,2016,29(10):734-741.DOI:10.3967/bes2016.098.
[10]史娅萍,朱宇宁,周丽琴,等.人乳头瘤状病毒基因型在宫颈疾病中的分布特点[J].中华检验医学杂志,2007,30(9):1009-1012.DOI:10.3760/j.issn:1009-9158.2007.09.013.
SHI Y P,ZHU Y N,ZHOU L Q,et al.Preliminary analysis of human papillomavirus genotype distribution in cervical diseases[J].Chinese Journal of Laboratory Medicine,2007,30(9):1009-1012.DOI:10.3760/j.issn:1009-9158.2007.09.013.
[11]LI C D,WU M H,WANG J D,et al.A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing,People's Republic of China[J].Cancer Epidemiol Biomarkers Prev,2010,19(10):2655-2664.DOI:10.1158/1055-9965.EPI-10-0212.
[12]陈仲波,朱笕青,俞华,等.1169例宫颈癌患者人乳头状瘤病毒感染状况分析[J].中华医院感染学杂志,2010,20(6):809-811.
CHEN Z B,ZHU J Q,YU H,et al.Human papillomavirus genotypes in 1169 cervical cancer patients[J].Chinese Journal of Nosocomiology,2010,20(6):809-811.
[13]CHAN P K,HO W C,CHAN M C,et al.Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide[J].PLoS One,2014,9(9):e107573.DOI:10.1371/journal.pone.0107573.
[14]DHAR J P,ESSENMACHER L,DHAR R,et al.The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus[J].Vaccine,2017,35(20):2642-2646.DOI:10.1016/j.vaccine.2017.04.001.